3SBio Inc. (TRSBF)

Market Cap	10.74B
Revenue (ttm)	1.27B
Net Income (ttm)	329.24M
Shares Out	n/a
EPS (ttm)	0.13
PE Ratio	32.61
Forward PE	12.85
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	3,918
Open	4.000
Previous Close	4.415
Day's Range	4.000 - 4.415
52-Week Range	0.723 - 4.740
Beta	0.74
RSI	64.88
Earnings Date	Aug 22, 2025

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC ex...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 5,577
• Stock Exchange: OTCMKTS
• Ticker Symbol: TRSBF

Financial Performance

In 2024, 3SBio's revenue was 9.11 billion, an increase of 16.53% compared to the previous year's 7.82 billion. Earnings were 2.09 billion, an increase of 34.93%.

Financial numbers in CNY